Evelyn D’An
About Evelyn D’An
Evelyn D’An is an independent director of Zoomcar Holdings, Inc. (ZCAR), serving since December 2023 and currently designated as a Class III director whose term expires at the 2026 annual meeting. She is a former Ernst & Young audit partner with over 18 years of client service across technology, retail, and consumer sectors, holds a B.S. in Accounting from SUNY Albany, and previously was a licensed CPA in New York (from July 9, 1990). She chairs Zoomcar’s Audit Committee and is recognized by the Board as an “audit committee financial expert.”
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ernst & Young | Audit Partner | 18+ years | Led audits across tech, retail, consumer products; deep financial reporting expertise |
| Enochian Biosciences (NASDAQ: ENOB) | Director | Mar 2018 – Apr 2021 | Audit; Nominating & Governance; Compensation |
| Summer Infant, Inc. (NASDAQ, sold Jun 2022) | Director | Nov 2016 – Jun 2022 | Chaired Compensation; member Audit; company sold to private buyer |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Backblaze, Inc. (NASDAQ: BLZE) | Director | Aug 2021 – present | Chairs Audit; member Compensation |
| GHD Group Pty Ltd | Director | Mar 2020 – present | Chairs Audit; member Global I&D Council and Risk Committee |
| NACD Florida | Board Chair | Current | Governance thought leadership; frequent governance speaker |
Board Governance
- Independence: The Board determined D’An is independent under Nasdaq rules and Rule 10A-3 of the Exchange Act.
- Committee assignments (current):
- Audit Committee: Chair; members John Clarke and Swatick Majumdar (all independent; D’An is financial expert).
- Compensation Committee: Members D’An and John Clarke; Clarke serves as chair.
- Tenure/classification: Class III; term expires at 2026 annual meeting.
- Attendance: In FY ended Mar 31, 2024, she attended 8 of 9 post-closing Board meetings (88.9%) and attended all Audit Committee meetings that year (4 meetings).
Fixed Compensation
Zoomcar’s non-employee director compensation framework and D’An’s actual cash fees:
| Item | Amount | Source |
|---|---|---|
| Annual Board cash retainer | $75,000 | |
| Committee member retainers | Audit: $10,000; Compensation: $6,000; Nominating/Gov: $4,000 | |
| Committee chair additional retainers | Audit: $10,000; Compensation: $6,000; Nominating/Gov: $4,000 | |
| FY 2024 cash fees (Apr 1, 2023–Mar 31, 2024) | $97,752 | |
| FY 2025 cash fees (Apr 1, 2024–Mar 31, 2025) | $101,000 |
Notes:
- Fees are paid quarterly in arrears and prorated for partial service periods.
Performance Compensation
Zoomcar grants RSUs to non-employee directors; vesting and award values are below.
| Metric | Policy / Award Design | Details |
|---|---|---|
| Initial RSU award (non-Chair) | $300,000 grant value | |
| Initial RSU award (Chairman) | $400,000 grant value | |
| Annual RSU award | $100,000 grant value (if no initial grant in last 12 months) | |
| Vesting | 1/3 on first anniversary of grant; then quarterly thereafter; service-based | |
| Change-in-control | RSUs accelerate in full upon change-in-control | |
| FY 2025 RSU award (D’An) | $5,154 fair value; Black-Scholes $2.92 per RSU |
Performance metrics table:
| Performance Metric | Weighting | Threshold/Target | Outcome |
|---|---|---|---|
| None disclosed for director RSUs | — | — | — |
Form S-8 and plan capacity context:
- Form S-8 filed Feb 11, 2025 to register 392,189 shares under the Incentive Plan; shareholders approved a one-time increase equal to 15% of shares outstanding on Mar 31, 2025, adding 369,311 shares; total currently issuable under the Plan is 370,955 shares (company intends to file an additional Form S-8 for the increase).
Other Directorships & Interlocks
| Company | Exchange/Ticker | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Backblaze, Inc. | NASDAQ: BLZE | Audit Chair; Comp member | No Zoomcar-related transactions disclosed |
| GHD Group Pty Ltd | Private | Audit Chair; I&D and Risk member | No Zoomcar-related transactions disclosed |
| Enochian Biosciences | NASDAQ: ENOB | Former Director | Past role; no current interlock |
| Summer Infant, Inc. | Former NASDAQ | Former Director (Comp Chair) | Company sold; no current interlock |
Expertise & Qualifications
- Former EY audit partner with extensive SEC reporting and internal controls experience; designated Audit Committee financial expert.
- Governance leadership: Chairs multiple audit committees; NACD Florida Board Chair; frequent governance speaker.
- Industry exposure across technology, consumer, and engineering/services, aligning with Zoomcar’s platform business.
Equity Ownership
| Category | Amount | As-of Date |
|---|---|---|
| Beneficial ownership (common shares) | 0 shares (shown as “--” in table) | |
| Beneficial ownership (common shares) | 0 shares (shown as “--” in table) | |
| RSU awards (FY 2025) | $5,154 fair value; $2.92 per RSU (number of RSUs not disclosed) |
Notes:
- No pledging or hedging of Zoomcar stock by D’An disclosed; no director ownership guidelines disclosed for Zoomcar; compliance status not disclosed.
- Indemnification agreements are in place for directors.
Governance Assessment
-
Strengths
- Independent director with deep audit and governance credentials; designated financial expert and Audit Committee chair.
- Active committee service; compensation oversight (member) and audit leadership enhance board effectiveness.
- Attendance: near-full Board participation post-closing FY 2024 and full Audit Committee attendance, indicating engagement.
-
Watch items
- Director equity awards accelerate on change-in-control—common in market practice but can be investor-unfriendly if not balanced by robust performance linkage (none disclosed for director RSUs).
- Beneficial ownership appears minimal (no common shares reported as of Dec 30, 2024); alignment relies on RSU grants rather than open-market holdings.
-
Conflicts/related-party exposure
- No related-party transactions disclosed involving D’An. Audit Committee reviews related party matters; several company-level related party transactions exist with other parties (e.g., Ananda Trust, Aegis/Cantor/J.V.B.), but none involve D’An.
-
Overall view
- D’An’s audit expertise and independence are positives for investor confidence. Attendance and committee leadership support effective oversight. Equity alignment is primarily via RSUs; lack of disclosed personal share ownership is neutral-to-slightly negative on “skin in the game,” but typical for many directors.